Therefore the increased expression of both PPARGC1A and targeted genes such as mTOR, IGF1R and MAP2K1, exclusively in day 110-MS fetuses (Fig. 4a and c) could explain the activated glucose and lipid metabolic processes and cell proliferation in MS at day 110 of gestation and participate to the better survival rate of MS neonates. This evidence concerns the gene PPARGC1A and myeloid sarcoma.